NHE3-Binding Compounds for Phosphate Transport Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperphosphatemia and chronic kidney disease are inadequate, as existing phosphate binders cause hypercalcemia and gastrointestinal discomfort, and there is a need for more effective phosphate transport inhibitors to reduce serum phosphate levels and slow renal failure progression.
Innovation Solution
Development of NHE3-binding and/or NHE3-modulating compounds that inhibit phosphate transport in the gastrointestinal tract and kidneys, designed to be substantially active locally without systemic absorption, reducing phosphate uptake and absorption from the intestine and kidneys.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If calcium salts are used to bind intestinal phosphate, then phosphate absorption is prevented, but hypercalcemia and serious side effects occur
Solution Approach 1:
The patent extracts the phosphate binding function from calcium salts and transfers it to a new class of compounds (MK-5108 and related compounds) that bind phosphate without releasing calcium, thereby eliminating the hypercalcemia problem while maintaining phosphate binding capacity
Solution Approach 2:
The invention changes the chemical and pharmacological parameters of phosphate binders by developing compounds with specific molecular structures (containing basic nitrogen atoms) that provide phosphate binding capability without the calcium release mechanism, fundamentally altering the drug's interaction with phosphate and calcium metabolism
2Object-affected harmful factors
If sevelamer is used as a phosphate binder, then calcium and aluminum are avoided, but high dosing frequency and gastrointestinal discomfort occur
Solution Approach 1:
The patent modifies the dosing parameters by developing compounds with higher phosphate binding efficiency per unit dose, reducing the total daily dose required from 7 grams to lower amounts, thereby decreasing gastrointestinal side effects and improving ease of administration
Solution Approach 2:
The invention uses composite molecular structures combining basic nitrogen-containing moieties with specific scaffolds to achieve enhanced phosphate binding affinity, allowing effective therapy at lower doses compared to sevelamer
3Quantity of substance
If phosphate binders are used to reduce serum phosphate levels, then hyperphosphatemia is treated, but cardiovascular calcification and renal failure progression occur
Solution Approach 1:
The patent develops a disposable, non-systemic phosphate binder that acts locally in the gastrointestinal tract to bind phosphate before absorption, preventing phosphate from entering the bloodstream and causing downstream calcification and renal damage
Solution Approach 2:
The compound MK-5108 acts as an intermediary substance in the gastrointestinal tract that intercepts phosphate from dietary sources, preventing its systemic absorption and subsequent deposition in cardiovascular tissues and kidneys
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively lower serum phosphate levels, reduce dietary phosphate uptake, and slow renal disease progression, minimizing systemic side effects and improving cardiovascular and bone health outcomes.
Implementation Method 1
phosphate absorption in the upper intestine is mediated at least in part by a carrier-mediated mechanism which couples the absorption of phosphate to that of sodium
Data Source
AI summary
Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.